A randomized, double-blinded, placebo-controlled trial to assess the antidepressant effects of the NMDA antagonist, CP-101 606 [traxoprodil], in patients with treatment refractory major depressive disorder
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2008
At a glance
- Drugs Paroxetine; Traxoprodil
- Indications Depression; Major depressive disorder
- Focus Therapeutic Use
- 01 Dec 2008 Results were published in the Journal of Clinical Psychopharmacology.
- 02 Nov 2005 New trial record.